Prestwick's Xenazine wins US approval for Huntington's disease
This article was originally published in Scrip
Executive Summary
The US FDA has approved Prestwick Pharmaceuticals' Xenazine (tetrabenazine) for the treatment of chorea (involuntary movements) in Huntington's disease. The drug will be available later this year.